MACE (Major Adverse Cardiovascular Events)
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
Definition
Major adverse cardiovascular events — the composite endpoint CV trials are built on, usually cardiovascular death plus nonfatal myocardial infarction plus nonfatal stroke. SELECT showed a 20% relative reduction, SUSTAIN-6 26%, LEADER 13%. The effect tracks weight loss loosely but exceeds what weight loss alone accounts for.
Top GLP-1 cardiovascular studies →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Major trials
Where the evidence lives
- Top GLP-1 cardiovascular studies
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers